The Fast Money traders share their final trades of the day.» Read More
Global business leaders eyeing expansion into India will be closely watching the outcome of the country’s general elections due to conclude on May 16.
CNBC's David Faber asks investor Carl Icahn if he succeeded in his eBay and Apple campaigns. Icahn also discuss his plans to seed other activist funds.
Bill Ackman also tells CNBC that Allergan's poison-pill defense doesn't make his takeover bid more difficult.
William Ackman, Pershing Square Capital Management, explains how his partnership with Valeant is structured. And J. Michael Pearson, Valeant chairman & CEO, discusses why he partnered with Ackman instead of pursing Allergan alone. Creating shareholder value is our job, says Pearson.
William Ackman, Pershing Square Capital Management, explains why he is helping Valeant buy Allergan.
J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, weighs in on news that Allergan has adopted a "poison pill" defense strategy. Also Pearson shares his thoughts on adding some of Allergan's notable cosmetic products like Botox and Restasis to its growing arsenal.
J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, explains why he decided to pursue Allergan and shares his R&D business model, with CNBC's Kate Kelly. This year we are launching 19 products in the United States, says Pearson.
William Ackman, Pershing Square Capital Management, explains why he decided to team up with Valeant Pharmaceuticals to make a play for Allergan.
Drugmakers eager to satisfy shareholders are wheeling, dealing, and in one case even making trades like a pro sports team looking to shake up its roster.
Comcast may divest about 4 million subscribers after its merger with Time Warner Cable and may sell a portion to Charter Communications.
Zhu Xinli, Chairman of China Huiyuan Juice Group, the country's biggest juice maker, says it can learn from Suntory's technology to provide high-quality tea.
Discussing new technology in the Permian, growing market in North America, and higher earnings, with Dave Lesar, Halliburton chairman, president and CEO.
The Fast Money traders share their final trades of the day.
The Fast Money traders take a look at today's biggest market movers.
Walgreen's pending acquisition of Alliance Boots can mean lower taxes and a better company, according to activist investor Barry Rosenstein.
More than half the revenue from Botox comes from therapeutic, not cosmetic, use. And its potential is helping to make Allergan an attractive target.
One of Valeant's top shareholders on Tuesday threw his support behind its proposed takeover bid for Botox-maker Allergan.
CNBC's David Faber and Jeffrey Ubben, ValueAct Capital Partners CEO, discuss the job performance of Microsoft CEO Satya Nadella and the likelihood of the Nokia deal closing.
CNBC's David Faber and Jeffrey Ubben, ValueAct Capital Partners CEO, discuss Valeant Pharmaceuticals bid for Allergan and why Valeant needed investor Bill Ackman involved in the deal.
The "Squawk on the Street" news team discuss all the M&A activity going on in pharma after Novartis is reported to be purchasing GlaxoSmithKline's oncology products unit for $14.5 billion. Separately Novartis is selling its animal health division to Eli Lilly for $5.4 billion in cash.
Get the best of CNBC in your inbox
The U.S. energy renaissance has coincided with a stealthy boom in energy-related stocks.
Carlyle has raised $698 million for its dedicated Africa fund, nearly $200 million above its initial target.
CNBC.com Enterprise Reporter Lawrence Delevingne discusses how the private equity industry views Africa.